Current knowledge of immunosuppression as a risk factor for skin cancer development
Journal
Critical Reviews in Oncology/Hematology
ISSN
1040-8428
Date Issued
2022
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Subjects
carcinoma
;
squamous cell
;
hiv
;
immunosuppression
;
immunosuppressive agents
;
melanoma
;
primary immunodeficiency diseases
;
skin neoplasms
;
transplant recipients
;
carcinoma, squamous cell
;
humans
;
immunosuppression therapy
;
immunosuppressive agents
;
risk factors
;
skin neoplasms
;
azathioprine
;
calcineurin inhibitor
;
corticosteroid
;
cyclosporine
;
gamma interferon
;
immunosuppressive agent
;
interleukin 1
;
interleukin 10
;
interleukin 13
;
interleukin 4
;
interleukin 5
;
interleukin 6
;
interleukin 8
;
macrophage inflammatory protein 1alpha
;
mammalian target of rapamycin inhibitor
;
methotrexate
;
monocyte chemotactic protein 1
;
mycophenolate mofetil
;
rantes
;
sirolimus
;
stromal cell derived factor 1
;
tacrolimus
;
tumor necrosis factor
;
tumor necrosis factor inhibitor
;
voriconazole
;
immunosuppressive agent
;
adaptive immunity
;
antigenic escape
;
cancer growth
;
cancer incidence
;
carcinogenesis
;
cause of death
;
dendritic cell
;
disease association
;
disease severity
;
graft recipient
;
human
;
human immunodeficiency virus
;
human immunodeficiency virus infection
;
immune editing
;
immune response
;
immunity
;
immunosuppressive treatment
;
kaposi sarcoma
;
lymphocyte
;
melanoma
;
merkel cell carcinoma
;
mortality rate
;
myeloid derived suppressor cell
;
nutritional status
;
organ transplantation
;
prevalence
;
primary cutaneous lymphoma
;
protein expression
;
review
;
risk factor
;
skin cancer
;
squamous cell skin carcinoma
;
suppressor cell
;
treatment duration
;
tumor invasion
;
tumor microenvironment
;
tumor-associated macrophage
;
adverse event
;
pathology
;
risk factor
;
skin tumor
;
squamous cell carcinoma